- Funding to support GMP manufacture of VesiculoVax™-vectored vaccines for Zaire-Ebola virus, Sudan-Ebola virus, and Angola-Marburg virus that will be blended into a single formulation; rapid follow-up Phase 1 clinical trial planned -
BALTIMORE, Md., Oct. 31, 2014 /PRNewswire/ -- Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.
In addition, the USACC has contracted for clinical evaluation of the VesiculoVax™ Zaire-Ebola virus vaccine to meet the current outbreak in West Africa.
......
In July 2014, Profectus BioSciences and the GNL were awarded a 3 year $8.5M grant from the DOD/JVAP to support development of a lyophilized trivalent VesiculoVax™-vectored vaccine to protect against all major strains of Ebola and Marburg viruses delivered as aerosols.
The lyophilized trivalent vaccine is being tested in both pre-exposure and post-exposure studies to confirm protection of non-human primates from aerosol exposure to Ebola and Marburg viruses.
[link to www.prnewswire.com]
